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Abstract. Seven patients with steroid-resistant 
nephrotic syndrome were treated with FK 506 mono-
therapy. Four patients were children with focal scleros-
ing glomerulonephritis (FSGS). Three of these had 
evidence for chronic progressive renal disease con-
sisting of interstitial fibrosis and tubular atrophy on 
pretreatment renal biopsies. Two patients had also 
failed cyclosporin A (CsA), two cyclophosphamide, 
and one chlorambucil prior to treatment with FK 506. 
Three patients were adults with mesangial proliferative, 
membranoproliferative, and membranous glomerulo-
nephritis. Three patterns of response were noted: (1) a 
reduction in proteinuria to normal levels; (2) partial 
response (50% reduction) or; (3) no improvement. All 
patients except one experienced at least a 50% reduc-
tion in protein excretion at some time during FK 506 
therapy. Two of the children and one adult reduced 
protein excretion to essentially normal values. One 
patient had no sustained reduction in protein excretion 
and is considered to be a treatment failure, although 
her protein excretion was approximately 50% of pre-
treatment values intermittently. The drug was generally 
well tolerated. The most common side-effect was 
nephrotoxicity, which was reversible. These encour-
aging results suggest that FK 506 monotherapy may 
be effective in controlling the proteinuria of some 
patients with steroid-resistant nephrotic syndrome. The 
use of this drug may extend our understanding of the 
role of T lymphocytes and cytokines in the pathogen-
esis of glomerulonephritis. Further study of this agent 
in a larger population of patients is warranted. 
Introduction 
Steroid-resistant nephrotic syndrome (SRNS) is a 
group of disorders with diverse histological findings, 
which are by definition resistant to corticosteroids and 
to other therapy as well [1,2]. In most patients progres-
sion to end-stage renal disease is the ultimate outcome. 
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Recently protocols using high-dose intravenous 
corticosteroids have shown some promise but continue 
to be limited by the complications of these agents and 
limited success in reversing proteinuria [3-5]. The use 
of other immunosuppressants such as cyclophospham-
ide and chlorambucil have resulted in remissions in 
some patients but were also met with limited success, 
particularly in adult patients, as one-third of childhood 
FSGS patients respond to either prednisone and/or 
cyclophosphamide/CsA [6]. 
Recently cyclosporin A has been used to treat 
patients with nephrotic syndrome [6-11]. Since many 
forms of idiopathic nephrotic syndrome may be 
immunologically mediated with derangements in T 
lymphocyte function and the abnormal production of 
cytokines, the use of aT-cell-specific inhibitor may 
have obvious advantages [12]. The rationale for using 
cyclosporin A in nephrotic syndrome has recently been 
summarized by Borel [13]. The most compelling argu-
ment for the use of this class of agents has been the 
ability of cyclosporin A to prevent experimental forms 
of glomerulonephritis. Unfortunately cyclosporin has 
been least effective in patients with steroid-resistant 
nephrotic syndrome [8,9]. FK 506, a new immuno-
suppressant agent is more potent than cyclosporin on 
a molar basis and may cause less drug-induced 
hypertension. 
Cyclosporin A and FK 506 both bind to a similar 
class of cytosolic binding proteins (cis--trans peptidyl-
prolyl isomerase, collectively termed immunophilins) 
[14]. Since FK 506 also selectively inhibits CD4 + T 
helper lymphocyte activation and proliferation, we 
have begun a pilot trial of FK 506 in the management 
of steroid-resistant nephrotic syndrome. We have previ-
ously reported our encouraging experience with FK 506 
in two patients with steroid-resistant nephrotic syn-
drome [15]. In this report we will update and expand 
our experiences and observations. 
Subjects and methods 
Seven patients with steroid-resistant nephrotic syndrome 
were treated with FK 506 mono therapy (Table I). This study 
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Table 1. 
Patient Age start FK 506 Sex Histology Prior therapy Response to 
Age (disease onset) prior therapy 
I 2.5 (1.5) Male FSGS Pred, Cyphos No improvement 
2 40 (39) Male Mes. Prolif. GN Pred No improvement 
3 12 (9) Female FSGS Pred, ChlorA, CsA Partial response to CsA, 
later refractory 
4 13 (12) Male FSGS Pred, CsA (same as no. 3) 
5 2.5 (1.5) Male FSGS Pred, Cyphos, CsA (same as no. 3) 
6 20 (17) Male MPGN Pred No improvement 
7 32 (30) Male Membranous GN Pred No improvement 
GN, glomerulonephritis; FSGS, focal sclerosing GN; MPGN, membranoproliferative GN; CsA, cyclosporin A; Cyphos, cyclophosphamide; 
ChlorA, chlorambucil; Pred, prednisone. 
was approved by the institutional review boards of the 
Pittsburgh Children's and Presbyterian-University 
Hospitals. Appropriate informed consent was obtained from 
each patient or his or her guardian. All patients except 
patient nos 2 and 4 clearly had idiopathic nephrotic syn-
drome. Both of the latter patients had documented additional 
illnesses which might have been associated with glomerulo-
nephritis. Four patients with FSGS were children with age 
range of 2.5-13 years. Three were adults with age range of 
20--40 years. Six were male and one was female. Baseline 
renal biopsies were performed in all patient prior to initiating 
FK 506 therapy. Three of the four children with FSGS had 
interstitial fibrosis, and tubular atrophy on pretreatment 
biopsies, suggesting chronic renal insufficiency. The adults 
had more disparate histological findings. 
All patients in this series had been treated with corticos-
teroids, primarily oral prednisone, prior to entry into this 
study. In addition to corticosteroids, two of the four patients 
with FSGS had been unsuccessfully treated with cyclophos-
phamide, one patient with chlorambucil and two with cyclo-
sporin A. Patient no. 1 had been treated with 
cyclophosphamide (2 mg/kg/day) for only 2 days prior to 
starting FK 506. Corticosteroids were discontinued in all 
patients except patient no. 3 in whom 5 mg prednisone every 
other day was continued. In all cases prednisone was tapered 
before stopping the drug. 
FK 506 was administered orally in all patients with an 
initial dose of 0.15 mg/kg/day given twice daily. The dosage 
ofFK 506 was adjusted based upon drug level, renal function, 
and overall clinical state. Approximate desirable drug levels 
were values greater than 0.5 and less than 2.0 ng/m!. The 
minimal detectable level for this assay is 0.1 ng/m!. 
Adequate 24-h collections were confirmed in adults by 
accepting only specimens with creatinine excretions of at 
least 15 mg/kg/day in females and 20 mg/kg/day in males. 
Foley catheters were placed in all children. 
Results 
FK 506 reduced 24-h protein excretion, reaching nearly 
50% of pretreatment values in all patients (Table 2, 
Figures 1, 2). The maximal benefit occurred in most 
patients within the first 2 months. The treatment 
duration on FK 506 ranged from 5 to 14 months. 
Twenty-four-hour protein excretion decreased to 
subnephrotic range in four patients (nos. 1, 2, 5, and 
7) after 3 months of therapy (Table 2, Figure 2). In 
patient no. 6, after 6 months of FK 506, protein 
excretion decreased from 8.3 g to 1700 mg/day. FK 506 
therapy was temporarily discontinued by two patients 
(nos 1, and 2), which resulted in prompt relapses of 
proteinuria to pretreatment levels (Figure 3). The 
proteinuria corrected within days after reinstituting 
therapy in patient no. 1. In patient no. 2 FK 506 was 
reinstituted at half the dose prior to stopping the drug 
at the patient's own request. Improvement in pro-
teinuria was attained at this subtherapeutic dosage but 
he has again stopped the drug, with a full recurrence 
of nephrotic syndrome. 
One patient (no. 3) with FSGS experienced no sus-
tained reduction in protein excretion, although values 
reached approximately half of the pretreatment values 
on several occasions. FK 506 was discontinued after 5 
months of therapy. Serum creatinine (SCr) which had 
increased during therapy, declined to its pretreatment 
levels. After FK 506 was stopped cyclophosphamide 
was begun but the protein excretion returned to pre-
treatment levels (approximately 9 g/day). 
In another patient (no. 4), FK 506 concentrations 
only transiently increased within the therapeutic range. 
Concerns about compliance have prevented progressive 
dosage increases; however, this 13-year-old boy with 
sickle-cell anaemia experienced a decline in protein 
excretion from approximately 27 to 5.3 g. 
Consistent reductions in protein excretion to very 
low or undetectable values occurred in three patients 
(nos 1, 2, and 5): two children with FSGS and one 
adult with mesangial proliferative glomerulonephritis 
(Figure I). Both patients with FSGS had interstitial 
nephritis and tubular atrophy on pretreatment renal 
biopsies, although serum creatinine did not reflect this. 
Patient no. 5 had failed to respond to corticosteroids, 
cyclophosphamide, and cyclosporin A. In the two 
children, the reduction in protein excretion was dra-
matic, falling to their nadir within 1 month after 
starting FK 506. 
Control of oedema was improved in all patients 
when protein excretion declined. This clinical benefit 
was apparent even in patients without a significant 
increase in serum albumin. The most dramatic effects 
were seen in the three patients with near normal 
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Table 2. 
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Fig. 1. Urinary protein excretion in three patients with complete 
remissions of nephrotic syndrome under FK 506. Values at time 
zero equal pretreatment determinations. Data on patients no, I and 
no. 2 represent only data while patients were taking the drug, values 
from the periods of drug withdrawal have been omitted. 
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Fig. 2. Urinary protein excretions in four patients with partial 
responses to FK 506 therapy, Values at time zero equal pretreatment 
determinations. Therapeutic levels were seldom attained in patient 
no. 4. 
treatment protein excretions, but a benefit was also 
apparent in those with less significant reductions in 
proteinuria. This clinical improvement was not due to 
increased diuretic dosage, since this had been reduced, 
not increased. 
Creatinine clearance decreased in all patients after 
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Fig. 3. Urinary protein excretion in patient no. 1. FK 506 was 
discontinued twice resulting in recurrence of the nephrotic syndrome. 
The proteinuria resolved within days of reinstituting the drug. 
instituting FK 506. Renal function returned toward 
pretreatment values when the dosage was reduced or 
the drug was stopped (Figure 4). A renal biopsy was 
repeated in patient no. I after 7 months of therapy. 
This patient, with FSGS,. had interstitial nephritis and 
tubular atrophy on the pretreatment biopsy. Repeat 
biopsy revealed no worsening of interstitial nephritis 
or glomerulosclerosis; however, there was no improve-
ment in glomerular pathology. Areas of foot process 
fusion persisted on electron-microscopy. 
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Fig. 4. Creatinine clearance for all patients. In children values are 
expressed as cc/min./1.73 m2 , 
FK 506 in steroid-resistant nephrotic syndrome 
FK 506 was generally well tolerated. The most 
common side-effect was tremor, which occurred in the 
three adults but not in the children. The tremor 
resolved after reduction in FK 506 dosage and was 
considered to be evidence of overdosage. Vivid dreams 
were noted in two adult patients and diarrhoea was 
reported in one child and one adult. Hyperkalaemia 
responsive to fludrocortisone (0.1 mg twice per day) 
developed in two patients. Hypertension developed in 
one patient and worsened in a second after fludrocorti-
sone was started. None of the patients developed 
hyperuricaemia, but one developed hypomagnesaemia. 
Hyperglycaemia was not apparent in any patient. Two 
patients have permanently discontinued therapy: 
patient no. 3, who was termed a failure, and patient 
no. 2. The latter patient, who had stopped the drug 
earlier, moved to another country, and changed his 
primary physician who substituted a non-steroidal anti-
inflammatory agent for FK 506. No therapeutic 
improvement was apparent after I month of this 
new therapy. 
Discussion 
This pilot trial demonstrate that FK 506 can be 
effective in reducing proteinuria in some patients with 
steroid-resistant nephrotic syndrome. Three patterns 
of response seemed apparent: (1) rapid decline in 
proteinuria to near normal values; (2) approximately 
50% reduction in proteinuria; (3) no improvement. 
The mechanism of the antiproteinuric effect of 
FK 506 is probably multifactorial and may even vary 
according to histological classification. Potential modes 
of action of FK 506 include inhibition of T-cell-
mediated lymphokine production, improvement in 
glomerular basement membrane charge permselectivity 
independent of Iymphokine production, correction of 
a fundamental immunological defect, or a reduction in 
GFR. The amelioration of proteinuria, however, is 
probably due to reversible changes in the permselectiv-
ity of the basement membrane rather than a funda-
mental correction of an immunological defect. 
Evidence for this includes the prompt return of pro-
teinuria upon discontinuation of the drug and the lack 
of demonstrable improvement on follow-up renal 
biopsies. A reduction in GFR seen in most patients 
may playa role. However, in some patients the reduc-
tion in proteinuria appears greater than that expected 
for the degree GFR decline. This is most apparent in 
patients with the best results. The proteinuria remained 
very low even when FK 506 dosage had been tapered 
and creatinine clearance was very close to pretreatment 
levels. In trials with cyclosporin A similar to this series, 
the histological abnormalities persisted or worsened 
and proteinuria rapidly returned when the drug was 
stopped [8-10]. 
Recent reviews of cyclosporin A therapy for 
nephrotic syndrome suggests that steroid-resistant 
nephrotic syndrome is most refractory to this agent 
[8,9]. The response in patients with FSGS and inter-
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stitial fibrosis has prompted Meyrier to conclude 
recently that cyclosporin A is not indicated in FSGS 
with interstitial fibrosis [16]. In his study only 22% of 
patients with FSGS improved, and in patients with 
pre-existing interstitial nephritis this lesion progressed 
rapidly under cyclosporin therapy. In our series three 
of the four patients with FSGS had interstitial nephritis 
on pretreatment biopsies. Given our small sample size 
and the preliminary nature of this report, we cannot 
determine whether FK 506 will be more beneficial in 
patients with histological evidence of chronic renal 
disease than cyclosporin A. The complications of 
FK 506 therapy were, in general, not serious and easily 
reversed. The spectrum of side-effects with FK 506 has 
been previously reported by our group [17-20]. Acute 
nephrotoxicity represented by a reversible reduction in 
glomerular filtration (GFR) was the most frequent and 
serious. These studies in liver, kidney and heart trans-
plant patients treated with FK 506 suggest that revers-
ible elevations in serum creatinine are common and 
related to drug dosage and route of administration. 
Hyperkalaemia is a common complication of 
FK 506. The pathogenesis is unknown but it has 
generally responded to fludrocortisone in the setting 
of transplantation. Likely mechanisms include resist-
ance to aldosterone in renal epithelial cells or aldos-
terone deficiency, which may appear similar to type IV 
renal tubular acidosis. 
The starting dose of FK 506 is now considered to 
be excessive. We have now reduced the initial dose to 
approximately 0.1 mg/kg/day in an attempt to minim-
ize the nephrotoxicity while maintaining the drug's 
usefulness. The minimal effective dose has not been 
determined in most patients to date, so we cannot 
determine whether the persistent depression in renal 
function is a result of reversible FK 506 nephrotoxicity 
or the natural progression of renal failure. Since all of 
the histological lesions treated in this study tend to 
progress, future studies will require larger patient popu-
lations and extensive follow-up to answer this complex 
question. 
FK 506, like cyclosporin A, has not been universally 
effective in controlling proteinuria. This study is a pilot 
study and not structured to determine the relative 
efficacy of FK 506 compared to cyclosporin A. This 
study does suggest that some patients are highly 
responsive to this T-cell-directed (cytokine) therapy, 
which may support the role of these factors in the 
pathogenesis of glomerulonephritis. It further uncovers 
patients with partial or no improvement from this 
therapy. In these patients other factors such as B 
lymphocytes, cytokines not directly affected by immun-
ophilin-directed therapy, adhesion molecules, or eicos-
anoids, may play more important roles in sustaining 
the proteinuria and structural abnormalities. In 
Heymann nephritis different pathogenetic mechanisms 
dominate the induction and maintenance phases of 
this disease. Similar differences may occur in various 
forms of human glomerulonephritis. Future studies 
using anti-B-cell agents or monoclonal antibodies tc 
adhesion molecules in combination with immunophil· 
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in-directed therapy may be more efficacious in these 
refractory patients. 
In conclusion, FK 506 appears to be effective in 
controlling the proteinuria of steroid-resistant 
nephrotic syndrome in this pilot trial. The major 
important side-effect of FK 506 is nephrotoxicity, 
which appears to be reversible. Further work is needed 
to determine the minimal effective dose, the drug level 
required to induce and maintain a remission, and 
which histological groups are most likely to benefit. 
The potential benefit of combination therapy using 
drugs with different modes of action should be 
considered. 
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